PainReform (PRFX) Competitors $1.87 -0.08 (-4.10%) Closing price 05/21/2025 03:59 PM EasternExtended Trading$1.82 -0.05 (-2.67%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, AEZS, LIPO, and MTVAShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), Aeterna Zentaris (AEZS), Lipella Pharmaceuticals (LIPO), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Indaptus Therapeutics Genprex AIM ImmunoTech Chromocell Therapeutics Biofrontera Avalon GloboCare Soligenix Aeterna Zentaris Lipella Pharmaceuticals MetaVia PainReform (NASDAQ:PRFX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do insiders and institutionals hold more shares of PRFX or INDP? 37.3% of PainReform shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to PRFX or INDP? In the previous week, Indaptus Therapeutics' average media sentiment score of 1.50 beat PainReform's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment PainReform Neutral Indaptus Therapeutics Very Positive Which has more volatility & risk, PRFX or INDP? PainReform has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Do analysts rate PRFX or INDP? PainReform currently has a consensus target price of $8.00, suggesting a potential upside of 327.81%. Indaptus Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 2,136.84%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than PainReform.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRFX or INDP more profitable? Indaptus Therapeutics' return on equity of -177.27% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets PainReformN/A -450.64% -241.33% Indaptus Therapeutics N/A -177.27%-141.06% Does the MarketBeat Community prefer PRFX or INDP? Indaptus Therapeutics received 10 more outperform votes than PainReform when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 75.00% of users gave PainReform an outperform vote. CompanyUnderperformOutperformPainReformOutperform Votes375.00% Underperform Votes125.00% Indaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Which has higher valuation and earnings, PRFX or INDP? Indaptus Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPainReformN/AN/A-$9.34M-$147.33-0.01Indaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.26 SummaryIndaptus Therapeutics beats PainReform on 10 of the 14 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.76M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.018.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book0.026.466.804.50Net Income-$9.34M$143.98M$3.23B$248.18M7 Day Performance-1.58%2.03%1.53%0.23%1 Month Performance-16.52%4.11%10.05%12.39%1 Year Performance-37.67%-2.87%16.75%7.07% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.8075 of 5 stars$1.87-4.1%$8.00+327.8%-37.7%$3.76MN/A-0.014INDPIndaptus Therapeutics3.3455 of 5 stars$0.42+3.9%$8.50+1,941.8%-83.8%$6.68MN/A-0.246Gap DownGNPXGenprex0.9206 of 5 stars$0.28-3.3%$10.00+3,523.2%-88.2%$6.67MN/A0.0020Gap UpAIMAIM ImmunoTech1.4321 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.7%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.08-1.9%N/A-46.8%$6.59MN/A-0.734Gap DownBFRIBiofrontera2.7003 of 5 stars$0.68-1.8%$7.00+925.6%-42.1%$6.45M$37.32M-0.3070Earnings ReportAnalyst ForecastAnalyst RevisionGap UpALBTAvalon GloboCare0.5545 of 5 stars$3.87-0.5%N/A-11.0%$6.39M$1.33M-0.195Positive NewsUpcoming EarningsSNGXSoligenix0.9935 of 5 stars$1.96-1.3%N/A-68.8%$6.38M$840,000.00-0.2620AEZSAeterna ZentarisN/A$3.55+5.0%N/A-57.0%$6.37M$2.37M-0.2420Analyst ForecastLIPOLipella Pharmaceuticals0.9501 of 5 stars$2.45+1.9%N/A-49.7%$6.23M$536,357.00-0.584Positive NewsMTVAMetaVia1.8101 of 5 stars$0.70-3.9%$12.00+1,612.6%N/A$6.07MN/A0.008News CoverageAnalyst Forecast Related Companies and Tools Related Companies INDP Competitors GNPX Competitors AIM Competitors CHRO Competitors BFRI Competitors ALBT Competitors SNGX Competitors AEZS Competitors LIPO Competitors MTVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRFX Stock Free PRFX Stock Alerts